Akèy › Limfom
Etid klinik pou Limfom ap rekrite nan Etazini
142 etid pou Limfom ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX34 etid
- Boston, MA33 etid
- New York City, NY33 etid
- Washington, DC23 etid
- Baldwin Park, CA21 etid
- Chicago, IL20 etid
- Durham, NC17 etid
- Philadelphia, PA15 etid
- St. Louis, MO15 etid
- Cleveland, OH13 etid
- Edison, NJ12 etid
- Seattle, WA12 etid
- Atlanta, GA11 etid
- Rochester, MN11 etid
- Columbus, OH11 etid
- Nashville, TN11 etid
- Miami, FL11 etid
- Dallas, TX10 etid
- Salt Lake City, UT10 etid
- Los Angeles, CA10 etid
- Pittsburgh, PA10 etid
- Queens, NY10 etid
- Mountain View, CA9 etid
- Greenburgh, NY9 etid
- Denver, CO9 etid
- Milwaukee, WI9 etid
- Aurora, CO8 etid
- Birmingham, AL8 etid
- Portland, OR8 etid
- Cincinnati, OH8 etid
- Staten Island, NY8 etid
- East Norwalk, CT8 etid
- New Haven, CT7 etid
- Tampa, FL7 etid
- San Antonio, TX7 etid
- Omaha, NE7 etid
- Phoenix, AZ7 etid
- New Rochelle, NY7 etid
- Clifton, NJ6 etid
- Cedar Rapids, IA6 etid
Pa eta
- Alabama9 etid
- Arizona11 etid
- Arkansas3 etid
- Colorado16 etid
- Connecticut7 etid
- Distrik Columbia7 etid
- Florid25 etid
- Georgia15 etid
- Illinois23 etid
- Indiana6 etid
- Iowa6 etid
- Kalifòni40 etid
- Kansas7 etid
- Kentucky5 etid
- Maryland21 etid
- Massachusetts33 etid
- Michigan12 etid
- Minnesota14 etid
- Missouri17 etid
- Nebraska7 etid
- New Jersey18 etid
- New York42 etid
- North Carolina22 etid
- Ohio28 etid
- Oklahoma4 etid
- Oregon8 etid
- Pennsylvania24 etid
- South Carolina4 etid
- Tennessee15 etid
- Texas45 etid
- Utah13 etid
- Virginia10 etid
- Washington12 etid
- Wisconsin12 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07192471A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Ap rekriteFaz 2
1 Month – 17 Years · Tout sèks · Mizajou Sep 30, 2026 · NCT04570423CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Ap rekriteFaz 1/2
Laj 3 a 39 · Tout sèks · Mizajou Sep 30, 2026 · NCT05442515A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07015242Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07583810Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07014293Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Ap rekriteEtid obsèvasyon
Laj 3 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT01441089Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT00006518Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Ap rekriteFaz 1/2
Laj 18 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT03223610A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07013435Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Sep 28, 2026 · NCT00923507Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT03418038Epco, Zanu, Ritux for R/R FL or MZL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06563596Rutgers University Study of the Genetics of Blood Cancers
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 110 · Tout sèks · Mizajou Sep 25, 2026 · NCT07714044Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Ap rekriteFaz 1
24 Months – 18 Years · Tout sèks · Mizajou Sep 25, 2026 · NCT06441331A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Ap rekriteFaz 1/2
Jiska laj 25 · Tout sèks · Mizajou Sep 25, 2026 · NCT04094610Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06398457CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Ap rekriteFaz 2
Laj 18 a 99 · Tout sèks · Mizajou Sep 24, 2026 · NCT04083495Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT02974647Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT04301076Precise Oncology Interventions in Nutrition and Training (OnPoint)
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06534918Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT03258567A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07221500Collection of Tissue Samples for Cancer Research
Ap rekriteEtid obsèvasyon
2 Months · Tout sèks · Mizajou Sep 16, 2026 · NCT00900198Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Ap rekriteFaz 1
Laj 18 a 100 · Tout sèks · Mizajou Sep 15, 2026 · NCT05798897Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.